Women undergoing superovulation prior to assisted reproductive techniques eg, in vitro fertilisation (IVF). Anovulatory or oligo-ovulatory women.
Dosage/Direction for Use
SCWomen undergoing superovulation prior to assisted reproductive techniques eg, in vitro fertilisation (IVF) 1 vial (250 mcg) 24-48 hr after the last administration of an FSH or hMG prep. Anovulatory or oligo-ovulatory women 1 vial (250 mcg) 24-48 hr after optimal follicular growth stimulation is achieved. The patient is recommended to have coitus on the day of & the day after inj.
Contraindications
Hypersensitivity. Hypothalamic or pituitary tumours, ovarian enlargement or cyst due to other polycystic ovarian disease; gynaecological bleeding of unknown aetiology; ovarian, uterine or mammary carcinoma; extrauterine pregnancy in the previous 3 mth; active thromboembolic disorders; primary ovarian failure; sexual organ malformation & uterine fibroid tumors which is inappropriate w/ pregnancy. Post-menopausal women.
Special Precautions
Hypothyroidism, adrenocortical deficiency, hyperprolactinemia, pituitary or hypothalamic tumours should be evaluated prior to treatment. Patients w/ clinically significant systemic diseases where pregnancy could exacerbate the condition. Thromboembolic events. Pregnancy & lactation. Childn & adolescents.
Adverse Reactions
Headache, vomiting, nausea, abdominal pain, mild or moderate ovarian hyperstimulation syndrome, fatigue, local reaction at inj site, ectopic pregnancy; depression, irritability, restlessness; diarrhea, mild skin reactions (reversible skin rash), mastalgia.